# DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients

> **NCT01588587** · — · UNKNOWN · sponsor: **Nagaoka Red Cross Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Alogliptin
- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT01588587
- **Lead sponsor:** Nagaoka Red Cross Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-10
- **Primary completion:** 2017-10
- **Final completion:** 2017-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2012-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01588587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01588587, "DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01588587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*